XERS News and Press, Xeris Pharmaceuticals Inc. From 06/26/20

Xeris Pharmaceuticals (NASDAQ: XERS ) has priced its public offerings of 7.4M shares of common stock at $2.72/share for gross proceeds of ~$20.1M, and $75M of 5.00% Convertible Senior Notes due 2025. More news on: Xeris Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced the pricing of concurrent underwritten public offerings of 7,400,000 s...

Gainers:  Ekso Bionics EKSO  +138% . More news on: Puhui Wealth Investment Management Co., Ltd., Vaxart, Inc., PaySign, Inc., Stocks on the move, , Read more ...

Gainers:  ALLY +14.7% . BBD +7.9% . CLPS +7.1% . NVST +5.1% . HLX +4.1% . More news on: Ally Financial Inc., Banco Bradesco S.A., CLPS Incorporation, Stocks on the move, , Read more ...

Xeris Pharmaceuticals (NASDAQ: XERS ) commences concurrent public offerings of $20M of common stock and $60M of convertible senior notes due 2025. More news on: Xeris Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has commenced concurrent underwritten public offerings of $20,...

Xeris Pharma Reports Positive Topline Data for Insulin Trial Xeris Pharmaceuticals ( XERS ) reported positive data for its Phase 2 clinical trial for diabetes. The drug candidate XP-3924 is an o-formulation of pramlintide and insulin and the trial aimed to assess its potential in treati...

Xeris Pharmaceuticals (NASDAQ: XERS ) announces positive results from a Phase 2 clinical trial evaluating candidate XP-3924, a co-formulation of pramlintide and insulin, in adults with type 1 diabetes (T1D). More news on: Xeris Pharmaceuticals, Inc., Healthcare stocks news, Stocks on t...

XP-3924 resulted in a 62% reduction of hyperglycemia after a glucose challenge XP-3924 showed improved glucose control when compared to Humulin® R alone XP-3924 showed promising glucose control when compared to both Humulin® R and co-administered injections of Humulin&#x...

Results show a pre-treatment with a micro dose (150 µg) of Gvoke RTU Micro significantly prevented Exercise-Induced Hypoglycemia (EIH) during prolonged, moderate-to-high intensity aerobic exercise in a real-world setting with or without adjustment to insulin Study achieved all pri...